世界のヒトパピローマウイルス（HPV）関連疾患市場の規模、シェア、傾向分析レポート – 業界の概要と2032年までの予測

ヒトパピローマウイルス（HPV）関連疾患市場分析

ヒトパピローマウイルス (HPV) 関連疾患市場は、診断、ワクチン開発、治療オプションの進歩により、大幅な成長を遂げています。重要な技術的進歩の 1 つは、HPV 株をより正確かつ迅速に識別するためのハイスループット DNA シーケンシング技術の開発です。これらのツールにより、子宮頸がんやその他のがんを引き起こす高リスク HPV タイプの検出が向上し、早期診断と患者の転帰の改善に貢献します。

もう一つの大きな進歩は、より多くの HPV 株に対する防御を提供する 4 価ワクチンや 9 価ワクチンなどの HPV ワクチンの継続的な改良です。これらのワクチンは、子宮頸がん、肛門がん、中咽頭がんの予防に大きな効果を示しています。

非侵襲的 HPV 検出のための液体生検の使用が普及しつつあり、従来の生検方法に代わる方法を提供することで、早期診断がよりアクセスしやすく、より低侵襲なものとなっています。

HPV 関連疾患に対する認識の高まり、ワクチン接種プログラムの拡大、技術の進歩により、予防、早期発見、より効果的な治療に引き続き重点が置かれ、HPV 関連疾患市場は堅調な成長を遂げると予測されています。

ヒトパピローマウイルス（HPV）関連疾患市場規模

世界のヒトパピローマウイルス（HPV）関連疾患市場規模は、2024年に205億1,000万米ドルと評価され、2025年から2032年の予測期間中に4.62%のCAGRで成長し、2032年には294億3,000万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

ヒトパピローマウイルス（HPV）関連疾患の市場動向

「HPVワクチン接種プログラムの増加」

ヒトパピローマウイルス（HPV）関連疾患市場の成長を牽引する特定の傾向の1つは、世界中でHPVワクチン接種プログラムの採用が増加していることです。子宮頸がん、肛門がん、咽頭がんなどのHPV関連がんの発生率を減らすための世界的な取り組みにより、ワクチン接種を促進するための政府および医療関係者による多大な努力がもたらされています。たとえば、2023年に世界保健機関（WHO）は、低所得国で15歳までに90％の少女にワクチン接種を行い、ワクチンへのアクセスを拡大することを目指す取り組みを開始しました。この積極的なアプローチにより、認知度が高まり、ワクチン接種率が向上し、結果としてHPV関連疾患が減少し、市場の成長にプラスの影響を与えています。

レポートの範囲とヒトパピローマウイルス（HPV）関連疾患市場のセグメンテーション

ヒトパピローマウイルス（HPV）関連疾患市場の定義

Human papillomavirus (HPV) is a group of viruses linked to several disorders, primarily affecting the skin and mucous membranes. High-risk strains of HPV can cause cervical, anal, and oropharyngeal cancers, as well as other genital cancers. HPV is also responsible for genital warts and is associated with low-grade lesions that can progress to precancerous conditions in the cervix and other areas. While most HPV infections clear on their own, persistent infection with high-risk types can lead to long-term health problems, making vaccination and regular screenings critical in preventing these disorders.

Human Papillomavirus (HPV) Associated Disorders Market Dynamics

Drivers

• Growing Prevalence of HPV Infections

The growing prevalence of HPV infections is a major driver for the HPV-associated disorders market. With over 79 million Americans infected with HPV and millions more globally, the virus is especially common among sexually active individuals. This surge in HPV cases has led to a significant increase in demand for vaccines, such as Gardasil, which protects against multiple high-risk strains. In addition, there is a heightened need for diagnostic tests, including HPV DNA tests, and treatments for HPV-related conditions such as cervical cancer and genital warts. For instance, in 2023, The FDA approved the first vaccine for preventing cervical cancer caused by HPV, a breakthrough expected to reduce cervical cancer cases by up to 90%. This landmark approval marks a pivotal advancement in public health, offering robust prevention and paving the way for widespread adoption in global HPV immunization programs.

• Rising Focus on Preventive Healthcare

The rising focus on preventive healthcare is a significant driver for the HPV-associated disorders market. Globally, there is a growing emphasis on prevention, particularly through vaccination and early diagnosis. Vaccination programs, such as the widespread implementation of the Gardasil vaccine, aim to reduce HPV-related cancers such as cervical cancer. For instance, countries such as Australia have successfully implemented national vaccination programs, significantly reducing HPV infection rates and related diseases. Early detection methods, such as HPV DNA testing, also play a crucial role in identifying high-risk infections before they develop into cancer. This preventive approach is driving the demand for HPV vaccines, screenings, and related healthcare solutions, fueling market growth worldwide.

Opportunities

• Growing Adoption of HPV Vaccination in Developing Countries

The growing adoption of HPV vaccination in developing countries is a significant driver for the HPV-associated disorders market. With increasing availability and affordability, vaccines such as Gardasil and Cervarix are being introduced through government programs and non-governmental organizations. For instance, in countries such as India, the government launched a pilot HPV vaccination program in 2021, aiming to reduce cervical cancer rates, which are highly prevalent in the region. This initiative has boosted vaccination uptake and has been instrumental in reducing the long-term burden of HPV-related disorders. Such efforts are expected to expand the market by increasing access to prevention and supporting healthcare infrastructure in low- and middle-income nations.

• Advances in HPV Vaccines

The development of advanced HPV vaccines, such as Gardasil 9, has significantly expanded the market for prevention. Gardasil 9 offers protection against nine strains of HPV, including high-risk types responsible for cervical, anal, and throat cancers. This broader protection compared to earlier vaccines such as Gardasil, which targeted only four strains, has boosted vaccine adoption worldwide. In addition, newer vaccines are showing longer-lasting immunity with fewer doses, making them more attractive for public health programs. The increased effectiveness and extended protection of these vaccines are driving their inclusion in national immunization schedules, leading to a rise in vaccination rates, particularly in younger populations, further propelling market growth.

Restraints/Challenges

• High Treatment Costs

High treatment costs for HPV-related conditions, including cervical and other cancers, present a significant barrier to market growth. Treatments such as immunotherapies, vaccines, and surgical interventions are expensive, making them inaccessible to many individuals, particularly in low-income regions. The cost of vaccines such as Gardasil and the expense of long-term cancer treatments can strain healthcare systems, leaving many without adequate options. This financial burden limits the adoption of prevention strategies and treatment options, hindering efforts to reduce the global burden of HPV-related diseases. In many cases, the lack of affordable healthcare options exacerbates the challenges faced by individuals in need of care.   

• Limited Global Access to Vaccines

Limited global access to HPV vaccines poses a significant challenge for the market, particularly in lower-income countries. While HPV vaccines are readily available in high-income nations, financial constraints, and inadequate healthcare infrastructure in developing regions restrict their accessibility. The high cost of vaccines, combined with limited funding for vaccination programs, hinders widespread adoption. In addition, in many low-resource settings, there is insufficient awareness and infrastructure to support effective vaccine distribution. As a result, these barriers prevent large-scale vaccination efforts, ultimately limiting the potential market growth and the ability to reduce the global burden of HPV-related disorders. This inequality in access severely impacts market penetration.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Human Papillomavirus (HPV) Associated Disorders Market Scope

The market is segmented on the basis of indication, therapy, vaccine type, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

• Cervical Intraepithelial Neoplasia (CIN)
• Cervical Cancer
• Anal Intraepithelial Neoplasia (AIN)
• Anal Cancer
• Genital Warts
• Others

Therapy

• Medication
  • Anti-viral drugs
  • Other medications
• Surgery
  • Cryotherapy
  • Laser surgery
  • Other surgery types
• Treatment

 Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 Vaccine Type

• HPV9 Vaccine
• HPV4 Vaccine
• HPV2 Vaccine

Human Papillomavirus (HPV) Associated Disorders Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, indication, therapy, vaccine type, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the human papillomavirus (HPV) associated disorders market due to strong commercial sales of biologics in the U.S., rising healthcare expenditure, and the local presence of key manufacturers. The region's advanced healthcare infrastructure and increasing awareness also contribute significantly to the market's growth and leadership.

Asia-Pacific is expected to expand at a significant growth rate in the human papillomavirus (HPV) associated disorders market due to rapid economic development, improved healthcare infrastructure, and increasing disposable income. Rising awareness about HPV prevention and vaccination, coupled with government initiatives to enhance healthcare access, further supports the region's market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Human Papillomavirus (HPV) Associated Disorders Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Human Papillomavirus (HPV) Associated Disorders Market Leaders Operating in the Market Are:

• Merck & Co., Inc. (U.S.)
• AbbVie (U.S.)
• GSK plc (U.K.)
• Cytovation AS (Norway)
• Biocon (India)
• Pfizer Inc. (U.S.)
• AstraZeneca (U.K.)
• Novartis AG (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Eli Lilly and Company (U.S.)
• Advaxis (U.S.)
• アステラス製薬（日本）
• アムジェン（米国）
• バイエルン・ノルディック（デンマーク）
• サノフィ（フランス）
• モデルナ（米国）
• ロシュ（スイス）
• ブリストル・マイヤーズスクイブ（米国）
• エーザイ（日本）

ヒトパピローマウイルス（HPV）関連疾患市場の最新動向

• 2024年9月、ファイザーはESMO会議で包括的な腫瘍学ポートフォリオを披露し、50を超える同社主催の抄録を発表しました。これには、初期の結果と次世代の候補を強調した10の口頭発表とミニ口頭発表が含まれていました。これは、併用療法と癌治療への画期的なアプローチに焦点を当てた、腫瘍学における革新に対するファイザーの取り組みを強調するものであり、世界中の患者の治療オプションを大幅に強化する可能性があります。
• 2024年9月、メルクは日本人男性を対象としたガーダシル9の第3相試験で良好な結果を発表し、HPV関連の肛門性器持続感染の軽減に効果があることを実証しました。このマイルストーンは、ワクチンの世界的な適用性を強調し、HPV関連疾患の予防オプションの拡大に対するメルクの取り組みを強調し、HPVワクチン市場におけるリーダーシップを強化します。
• 2024年5月、ロシュはHPV自己採取ソリューションのFDA承認を取得し、子宮頸がん検査へのアクセスを向上させました。このイノベーションは、2030年までに子宮頸がんを撲滅するというWHOの取り組みと一致しており、女性に簡単な検査オプションを提供し、早期発見の重大な障壁に対処することで世界的な公衆衛生目標を推進します。
• メルク社は、2024年3月に、新しい治験用多価HPVワクチンと単回投与のGARDASIL 9レジメンの臨床試験を開始する予定です。これらの開発は、ワクチンの有効性とアクセス性を高め、HPV予防戦略を再構築するとともに、世界中でHPV関連疾患と闘うメルク社のリーダーシップを強化することを目的としています。
• 2023年9月、INOVIO Pharmaceuticalsは、HPV-6およびHPV-11を標的とする治験中のDNA医薬品INO-3107について、米国FDAから画期的治療薬の指定を受けた。標的T細胞反応を誘発するように設計されたINO-3107は、再発性呼吸器乳頭腫症やその他のHPV関連疾患の治療に有望であり、治療用HPVソリューションの範囲を広げる可能性がある。
• 2023年、FDAはHPVによる子宮頸がんを予防する初のワクチンを承認しました。これは、子宮頸がんの症例を最大90％削減すると期待される画期的な進歩です。この画期的な承認は、公衆衛生における極めて重要な進歩を示し、強力な予防を提供し、世界中のHPV予防接種プログラムでの広範な採用への道を開きます。

SKU-46054